- Home
- OSS vs AGEN Comparison
OSS vs AGEN Comparison
Compare OSS & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSS
- AGEN
- Stock Information
- Founded
- OSS 1998
- AGEN 1994
- Country
- OSS United States
- AGEN United States
- Employees
- OSS N/A
- AGEN N/A
- Industry
- OSS Computer Manufacturing
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OSS Technology
- AGEN Health Care
- Exchange
- OSS Nasdaq
- AGEN Nasdaq
- Market Cap
- OSS 62.7M
- AGEN 52.6M
- IPO Year
- OSS 2018
- AGEN 2000
- Fundamental
- Price
- OSS $2.49
- AGEN $2.86
- Analyst Decision
- OSS
- AGEN Buy
- Analyst Count
- OSS 0
- AGEN 4
- Target Price
- OSS N/A
- AGEN $8.00
- AVG Volume (30 Days)
- OSS 86.9K
- AGEN 814.8K
- Earning Date
- OSS 05-07-2025
- AGEN 05-12-2025
- Dividend Yield
- OSS N/A
- AGEN N/A
- EPS Growth
- OSS N/A
- AGEN N/A
- EPS
- OSS N/A
- AGEN N/A
- Revenue
- OSS $54,301,661.00
- AGEN $103,463,000.00
- Revenue This Year
- OSS $9.65
- AGEN $4.03
- Revenue Next Year
- OSS $11.43
- AGEN $5.57
- P/E Ratio
- OSS N/A
- AGEN N/A
- Revenue Growth
- OSS N/A
- AGEN N/A
- 52 Week Low
- OSS $1.82
- AGEN $1.38
- 52 Week High
- OSS $4.88
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- OSS 54.95
- AGEN 62.99
- Support Level
- OSS $2.33
- AGEN $2.87
- Resistance Level
- OSS $2.90
- AGEN $3.16
- Average True Range (ATR)
- OSS 0.19
- AGEN 0.34
- MACD
- OSS 0.05
- AGEN 0.02
- Stochastic Oscillator
- OSS 57.83
- AGEN 64.29
About OSS One Stop Systems Inc.
One Stop Systems Inc designs, manufactures, and markets specialized rugged high-performance compute ("HPC"), high-speed switch fabrics, and storage systems, which are designed to target edge applications for artificial intelligence ("AI") / machine learning ("ML"), sensor processing, sensor fusion, and autonomy. The company operates in two reportable segments; OSS designs and manufactures high-performance customized computers and flash arrays, in-flight entertainment & connectivity. Bressner operates as a system integrator with standard and custom all-in-one hardware systems and components for many kinds of industrial environments. The company generates the majority of its revenue from the Bresssner segment.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).